Clinical Trial Update: Methylprednisolone in Patients with Cognitive Deficits in Post-COVID-19 Syndrome (PCS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating methylprednisolone for cognitive deficits in Post-COVID-19 syndrome; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-covid-19 Syndrome

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Post-COVID-19 Syndrome | Phase 2 | Status: UNKNOWN